KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to 45.57%.

  • Eli Lilly's EBITDA Margin rose 75200.0% to 45.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.16%, marking a year-over-year increase of 92600.0%. This contributed to the annual value of 35.92% for FY2024, which is 58600.0% up from last year.
  • Eli Lilly's EBITDA Margin amounted to 45.57% in Q3 2025, which was up 75200.0% from 45.13% recorded in Q2 2025.
  • Eli Lilly's 5-year EBITDA Margin high stood at 45.57% for Q3 2025, and its period low was 21.46% during Q2 2021.
  • In the last 5 years, Eli Lilly's EBITDA Margin had a median value of 30.4% in 2021 and averaged 31.91%.
  • In the last 5 years, Eli Lilly's EBITDA Margin plummeted by -99300bps in 2023 and then soared by 115000bps in 2025.
  • Eli Lilly's EBITDA Margin (Quarter) stood at 29.44% in 2021, then dropped by -3bps to 28.44% in 2022, then rose by 13bps to 32.19% in 2023, then rose by 23bps to 39.44% in 2024, then increased by 16bps to 45.57% in 2025.
  • Its EBITDA Margin was 45.57% in Q3 2025, compared to 45.13% in Q2 2025 and 41.38% in Q1 2025.